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A B S T R A C T
Background
People with cystic fibrosis, who are chronically colonised with the organism Pseudomonas aeruginosa, often require multiple courses of
intravenous aminoglycoside antibiotics for the management of pulmonary exacerbations. The properties of aminoglycosides suggest
that they could be given in higher doses less often.
Objectives
To assess the effectiveness and safety of once-daily versus multiple-daily dosing of intravenous aminoglycoside antibiotics for the
management of pulmonary exacerbations in cystic fibrosis.
Search methods
We searched the Cystic Fibrosis Specialist Register held at the Cochrane Cystic Fibrosis and Genetic Disorders Group’s editorial base,
comprising references identified from comprehensive electronic database searches, handsearching relevant journals and handsearching
abstract books of conference proceedings.
Date of the most recent search: 25 November 2013.
Selection criteria
All randomised controlled trials, whether published or unpublished, in which once-daily dosing of aminoglycosides has been compared
with multiple-daily dosing in terms of efficacy or toxicity or both, in people with cystic fibrosis.
Data collection and analysis
The two authors independently selected the studies to be included in the review and assessed the risk of bias of each study. Data were
independently extracted by each author. Authors of the included studies were contacted for further information. As yet unpublished
data were obtained for one of the included studies.
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Main results
Fifteen studies were identified for possible inclusion in the review. Four studies reporting results from a total of 328 participants were
included in this review. All studies compared once-daily dosing with thrice-daily dosing. One study had a low risk of bias for all criteria
assessed; the remaining three included studies had a high risk of bias from blinding, but for other criteria were judged to have either an
unclear or a low risk of bias.
There was no significant difference between treatment groups in: forced expiratory volume at one second, mean difference 0.33 (95%
confidence interval -2.81 to 3.48); forced vital capacity, mean difference 0.29 (95% confidence interval -6.58 to 7.16); % weight
for height, mean difference -0.82 (95% confidence interval -3.77 to 2.13); body mass index, mean difference 0.00 (95% confidence
interval -0.42 to 0.42); or in the incidence of ototoxicity, relative risk 0.56 (95% confidence interval 0.04 to 7.96). The percentage
change in creatinine significantly favoured once-daily treatment in children, mean difference -8.20 (95% confidence interval -15.32 to
-1.08), but showed no difference in adults, mean difference 3.25 (95% confidence interval -1.82 to 8.33).
Authors’ conclusions
Once- and three-times daily aminoglycoside antibiotics appear to be equally effective in the treatment of pulmonary exacerbations of
cystic fibrosis. There is evidence of less nephrotoxicity in children.
P L A I N L A N G U A G E S U M M A R Y
Giving aminoglycoside antibiotics intravenously once daily compared to giving them several times per day in people with cystic
fibrosis
Cystic fibrosis is a serious genetic disorder which affects the lungs and the exocrine glands (sweat glands and others). Most people with
cystic fibrosis develop persistent lung infections and they may receive frequent courses of intravenous antibiotics. Giving the antibiotics
once per day reduces the cost and the time involved, compared to giving several doses per day. This review includes four trials with a total
of 328 people. All the trials compared once-a-day dosing with three times-a-day dosing. The review found that giving the antibiotics
once per day was just as good at treating lung infections in people with cystic fibrosis as giving them more frequently. The review also
found that giving the antibiotics once per day appeared to be less toxic to the kidneys in children. There were no differences between
the different treatments for other outcomes. While once-daily treatment can be just as effective and more convenient than three-times
daily treatment, we recommend further studies to look at the long-term safety of this treatment schedule.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most common serious autosomal reces-
sive genetic disorder in theCaucasian population. It is estimated to
occur in 1 in 2500 births and about one person in 25 carries the de-
fective gene. Progressive pulmonary deterioration is the principal
cause of CF-related mortality and morbidity. People with CF have
an increased susceptibility to chronic lung infections, especially
withPseudomonas aeruginosa (P. aeruginosa) (Davis 1996). Most
antibiotics used for treatment are administered intravenously and
given for about two weeks (David 1986).
Description of the intervention
People with CF receive frequent and repeated courses of intra-
venous antibiotics throughout their lifetime. The current recom-
mendation for intravenous antibiotic treatment of pulmonary ex-
acerbations in people colonised with P. aeruginosa is a combination
of two antibiotics with different mechanisms of action (CF Trust
2009; Flume 2009). Combination antibiotic therapy, which has
been shown to produce a synergistic effect in vitro (Weiss 1995),
may limit the emergence of antibiotic resistant strains of P. aerug-
inosa (Cheng 1996). However, single versus combination intra-
venous antibiotic therapy in CF is the subject of another Cochrane
review which found no clear evidence of benefit for combina-
tion therapy, though there was a trend to less antibiotic resistance
(Elphick 2005). Previously, the majority of people with CF re-
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ceived an aminoglycoside, as part of their intravenous antibiotic
regimen, most commonly given in three divided doses (Tan 2002).
However a recent survey of prescribing practices in the UK has
shown that a once-daily regimen is usual practice in 86% of UK
CF centres (Smyth 2013).
How the intervention might work
Aminoglycosides demonstrate concentration dependent killing
and the post-antibiotic effect (Spivey 1992). Concentration de-
pendent killing means that the bactericidal action of aminoglyco-
sides is related to the peak concentration of antibiotic achieved.
Greater bactericidal effect occurs at concentrations exceeding the
minimum inhibitory concentration (MIC). The post-antibiotic
effect is a phenomenon in which the bactericidal action of the
aminoglycoside continues even after the antibiotic has been cleared
and its concentration has fallen below the MIC.
These pharmacological properties suggest that aminoglycosides
could be given in higher concentrations with an extended dos-
ing interval. There have been many randomised controlled trials
(RCTs) comparing once-daily with thrice-daily aminoglycoside
treatment in participants without CF and these have been the sub-
ject of a meta-analysis (Barza 1996). This study reports that once-
daily dosing is as effective, and perhaps safer, than the standard
thrice-daily dosing regimen. However, the results of these studies
cannot be directly extrapolated to the CF population, as plasma
clearance is more rapid in people with CF (de Groot 1987). Fur-
thermore, people with CF are vulnerable to cumulative side effects
from antibiotics as they receive recurrent and prolonged courses
of treatment.
Why it is important to do this review
The use of intravenous aminoglycosides is limited by their well-
recognised toxicity, affecting the inner ear and the kidney. Before
any change in dosing interval can be recommended, the relative
toxicity of once and multiple-daily dosing must be evaluated.
Once-daily aminoglycoside dosing has major advantages to people
with CF and their families, especially if they receive their antibi-
otics at home. In addition there are cost implications in reducing
the use of consumables and the time taken to prepare and deliver
antibiotics.
This is an updated version of the previously published review (
Smyth 2000; Smyth 2006; Smyth 2010; Smyth 2012).
O B J E C T I V E S
To assess the efficacy and safety of once-daily versus multiple-daily
intravenous aminoglycoside dosing in the treatment of pulmonary
exacerbations in CF. The hypotheses will be tested that once-daily
intravenous aminoglycoside dosing is:
• as effective as multiple-daily dosing (as measured by the
change in lung function over a course of antibiotic treatment)
• no more toxic than multiple-daily dosing (as measured by
renal and auditory toxicity).
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs, whether published or unpublished, and of parallel or cross-
over design. Studies using inappropriate forms of randomisation,
such as alternate allocation, will not be considered. Where it is
not clear, from the paper or the abstract, whether participants
have been randomised appropriately, the authors will be contacted
directly.
Types of participants
People with CF, who have been diagnosed by sweat test or genetic
testing or both, regardless of age or clinical severity.
Types of interventions
Once-daily dosing compared to multiple-daily dosing of intra-
venous aminoglycoside antibiotics for pulmonary exacerbations in
CF.
Where possible, a pulmonary exacerbation will be defined as four
or more of the following 12 symptoms or signs: change in spu-
tum; new or increased haemoptysis; increased cough; increased
dyspnoea; malaise, fatigue or lethargy; temperature above 38º C;
anorexia or weight loss; sinus pain or tenderness; change in sinus
discharge; change in physical examination of the chest; decrease in
pulmonary function by 10% or more from a previously recorded
value; radiographic changes indicative of a pulmonary infection
(Fuchs 1994). Where there is no such definition of an exacerba-
tion we will use the definition provided in the trial report.
Types of outcome measures
Primary outcomes
1. Lung function measurements
i) forced expiratory volume at one second (FEV1)
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ii) forced vital capacity (FVC)
iii) forced expiratory flow in mid expiration (FEF25−75%)
We compared the change in values from the start of antibiotic
treatment with those taken at the end of treatment.
Secondary outcomes
1. Nutritional status
i) weight gain
ii) body mass index (BMI)
iii) z scores
2. Time to first exacerbation requiring intravenous antibiotics
3. Antibiotic resistance patterns following treatment
4. Ototoxicity (defined as an increase in auditory threshold of
20 dB or more over any frequency range)
5. Nephrotoxicity (comparison of the percentage change in
creatinine over baseline)
6. Possible adverse events associated with aminoglycoside
infusion (e.g. vestibular changes, tinnitus, anaphylaxis)
7. Quality of life measures (if well-validated scores are
available e.g. Cystic Fibrosis Quality of Life - Revised (CFQ-R)
(Quittner 2009))
Search methods for identification of studies
Electronic searches
Relevant studies were identified from the Group’s Cystic Fibrosis
Trials Register using the terms: (intravenous OR not stated) AND
(tobramycin OR amikacin OR gentamicin OR netilmicin OR
sisomicin OR neomycin).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
quarterly searches of MEDLINE, a search of EMBASE to 1995
and the prospective handsearching of two journals -Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work is
identified by searching through the abstract books of three major
cystic fibrosis conferences: the International Cystic Fibrosis Con-
ference; the European Cystic Fibrosis Conference and the North
American Cystic Fibrosis Conference. For full details of all search-
ing activities for the register, please see the relevant sections of the
Cystic Fibrosis and Genetic Disorders Group Module.
Date of the most recent search of the Group’s CF Trials Register:
25 November 2013.
Data collection and analysis
Selection of studies
Two authors independently selected studies for inclusion in the
review. They resolved any disagreements by negotiation.
Data extraction and management
Two authors independently extracted data and resolved any dis-
agreements by negotiation. The authors collected data for the out-
come events listed above.
Assessment of risk of bias in included studies
Two authors assessed the risk of bias in the included studies by
following the domain-based assessment as recommended in The
Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011). They assessed the following domains:
• sequence generation;
• allocation concealment;
• blinding (if it took place and who was blinded);
• incomplete outcome data;
• selective reporting;
• other sources of bias.
On the basis of these assessments, the authors attributed a high
or low or unclear risk of bias for each domain to each study. For
example, if the randomisation sequence was generated using ran-
dom number tables or a computer, there would be a low risk of
bias for this domain.
Measures of treatment effect
For dichotomous variables (such as adverse events) the authors
used risk ratio and calculated a pooled estimate of treatment effect
across all studies. For continuous variables, such as lung function,
the authors pooled the treatment effect across all studies, using the
mean difference.
Unit of analysis issues
When conducting a meta-analysis combining results from cross-
over studies we planned to use the methods recommended by
Elbourne (Elbourne 2002).One of the included trials was of cross-
over design; however, we were not able to obtain first-arm data and
have therefore only reported data from this study narratively. If
full data from cross-over studies become available, the authors will
use first-arm data, where possible, but only consider the efficacy
outcomes.
Dealing with missing data
If data were missing, the authors attempted to contact the study
investigators for clarification.
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Assessment of heterogeneity
When sufficient studies are included in the review, the authors will
test for heterogeneity between study results using the I2 statistic
(Higgins 2003). This measure describes the percentage of the vari-
ability in effect estimates that is due to heterogeneity rather than
chance. The authors plan to use the following interpretation of
the statistic:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
The authors planned to compare original study protocols to final
published papers to identify any selective reporting. If the original
study protocols were not available, the authors examined the final
published papers to identify any outcomes stated as being mea-
sured, but not reported in the study results.
Weplanned to assess publicationbias by visual inspection of funnel
plots, if we had been able to include and combine at least 10
studies.
Data synthesis
We have analysed the included data using a fixed-effect model. If
investigation of the studies indicates an at least substantial level
of heterogeneity (over 50% using the I2 statistic) among those in-
cluded in an analysis, the authors will use a random-effects model.
Subgroup analysis and investigation of heterogeneity
Furthermore, if there is a substantial or considerable level of het-
erogeneity (as defined above) identified and sufficient studies in-
cluded in the review, the authors will perform subgroup analysis,
looking at the pre-defined subgroups of children and adults.
Sensitivity analysis
Sensitivity analysis will be undertaken if there is risk of small study
effects and if sufficient studies are included in the review.
R E S U L T S
Description of studies
Results of the search
Fifteen studies with publications were found by the searches. Four
studies were included in the review; 10 studies were excluded from
the review; one cross-over study is currently listed under ’Studies
awaiting classification’ while we seek first-arm data from the study
investigators (Al Ansari 2006). We are aware of one study, pre-
viously listed as ongoing in this review which was a multicentre
RCT of once-daily versus thrice-daily dosing of tobramycin in the
USA funded by the CF Foundation, treating participants with
tobramycin (12 mg/kg/day) plus the usual beta-lactam, given ei-
ther once daily or thrice daily (Tureen 2001). This study failed
to recruit a sufficient number of participants and was terminated
without any data being made available.
Please see the PRISMA diagram illustrating the flow of studies in
the review process (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Four studies, with a total of 328 participants completing treat-
ment per protocol, fulfilled the inclusion criteria for this review
(Riethmueller 2009; Smyth 2005; Vic 1998; Whitehead 2002).
The four studies evaluated the efficacy and toxicity of once versus
thrice-daily dosing of intravenous tobramycin for a pulmonary
exacerbation. One study also evaluated the use of continuous
ceftazidime infusions, which is beyond the remit of this review
(Riethmueller 2009). No studies were found, which compared
once-daily aminoglycoside dosingwith any other frequency of dos-
ing. All studieswere unblinded, apart fromone (Smyth2005).One
study was cross-over in design (Riethmueller 2009), the remain-
ing three studies were parallel (Smyth 2005; Vic 1998; Whitehead
2002). Data were recorded at the end of the treatment course with
no measures of longer-term outcomes.
The first study included22participants: 12 in the once-daily group
(8 male) age range 5.6 years to 19.3 years and 10 in the thrice-
daily group (6 male) age 7.4 years to 17.2 years. (Vic 1998). The
study was a randomised parallel group study but was not blinded.
The total daily dose of tobramycin in each group was 15 mg/kg/
day. Tobramycin was given in combination with ceftazidime, 200
mg/kg/day. Participants received 14 days of antibiotic treatment
and adjuvant treatment remained unchanged. Outcome measures
were calculated as mean change with standard deviation and in-
cluded lung function, nutritional status and inflammatory mark-
ers measured at the start and end of treatment. An assessment of
adverse effects was measured by comparing cochlear and renal in-
dices evaluated at the start and end of treatment.
The second study studied adults (Whitehead 2002). A total of
60 participants were studied, of whom 49 completed the study:
30 in the once-daily group (16 male) age range 15 years to 47
years and 19 in the thrice-daily group (11 male) age range 16 years
to 32 years. The total daily dose in each group was 10 mg/kg/
day. Tobramycin was given in combination with a beta-lactam an-
tibiotic, chosen by the clinician (either piperacillin, piperacillin/
tazobactam, aztreonam, azlocillin, imipenem, meropenem or cef-
tazidime). Participants received 12days of antibiotic treatment and
adjuvant treatment remained unchanged. Outcome measures in-
cluded lung function, nutritional status and inflammatory mark-
ers, measured at the start and end of treatment. An assessment
of adverse effects was measured by comparing cochlear and renal
indices evaluated at the start and end of treatment. Participant
preference of treatment regimens was reported, but as this was an
unblinded study, this was interpreted with caution. Intention-to-
treat analysis has not been performed in this study. Of the 60 par-
ticipants recruited to the study, 11 were withdrawn: four from the
once-daily group and seven from the thrice-daily group. Data are
missing from one participant in the thrice-daily group, leaving 18
participants on thrice-daily treatment whose data was analysed. Of
those that were withdrawn, eight participants (four on each regi-
men) developed resistance to tobramycin, two refused to continue
on thrice-daily treatment and one (in the thrice-daily group) was
withdrawn when an additional drug with nephrotoxic potential
was added to the treatment regimen.
The third study has now been published in full (Riethmueller
2009). There were three arms to this study:
• once-daily tobramycin with thrice-daily ceftazidime
(Treatment B);
• thrice-daily tobramycin with thrice-daily ceftazidime
(Treatment A); and
• once-daily tobramycin with continuous ceftazidime.
The continuous ceftazidime arm was excluded from this review.
The design of the study was an open-label, cross-over with a three-
month washout period. The total daily dose of tobramycin was
10 mg/kg/day. Thirty-eight participants were treated with Treat-
ment A and Treatment B. Eight participants were lost to follow-
up, three of whom were found to be colonized with resistant P.
aeruginosa strains and were therefore switched from ceftazidime to
meropenem.Therefore, 30 patients (20 female, 10male;mean age
11.2 years, age range 1.7 to 18.1 years) ultimately received both
Treatment A and Treatment B and could be analysed; 14 of these
received Treatment A first and Treatment B during a subsequent
course of intravenous antibiotics.
A further study, included in the review for the first time in 2006,
describes the results of a large, double-blind, parallel group, ran-
domised controlled trial of 244 participants (219 of whom com-
pleted the study per protocol) (Smyth 2005). As this was an equiv-
alence study, analysis was per protocol. Of those who completed
treatment, 107 (63 male) had once-daily treatment (age range 5.1
to 50.4 years) and 112 (68 male) had three-times daily treatment
(age range 5.5 to 43.3 years). Once-daily tobramycin was com-
pared with three-times daily dosing. A dose of 10 mg/kg/day of
tobramycin was used or, if the participant had received the drug
previously, the dose of tobramycin last shown to give therapeutic
levels. Treatment was for 14 days and tobramycin was combined
with ceftazidime 150 mg/kg/day in three divided doses. Outcome
measures were calculated as adjusted mean differences for contin-
uous variables such as FEV1 and creatinine. Changes in inflamma-
tory markers (C reactive protein), clinical score and hearing were
reported. Renal function was assessed by the percentage change in
creatinine over 14 days and change in concentrations of urinary
N-acetyl-beta-D glucosaminidase (NAG), a proximal tubular en-
zyme. Time to next intravenous antibiotics was also reported.
There were insufficient data to interpret changes in the antibiotic
resistance patterns of P. aeruginosa.
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Excluded studies
Ten studies were excluded as detailed in the table Characteristics
of excluded studies. Three studies were pharmacokinetic papers
(Aminimanizani 2002; Burkhardt 2006; Hamner 2006); one
study used alternate allocation of treatment (Heininger 1993); one
study compared monotherapy to combination therapy (Master
2001); one study was not blinded and measured efficacy on a
symptom score (Powell 1983); for one study (published as an ab-
stract) no outcome data were available and it was not clear whether
the participants were randomised (Postnikov 2007); one did not
include a once-daily arm of treatment (Adeboyeku 2011); the re-
maining two studies did not compare once-daily dosing with an-
other dosing schedule (Winnie 1991; Wood 1996).
Risk of bias in included studies
Allocation
In one study the randomisation schedule was generated using a
computer and stratified by centre and adult versus paediatric (
Smyth 2005). In two other studies randomisation tables were used
(Vic 1998;Whitehead 2002). All three of these studieswere judged
to have a low risk of bias from the generation of the randomisation
sequence (Smyth 2005; Vic 1998; Whitehead 2002). The fourth
study was described as randomised; it was a six-centre study in
which three centres randomised with three protocols and three
centres randomised with two protocols, but no actual details of
the randomisation process were given, so this study was therefore
judged to have an unclear risk of bias (Riethmueller 2009).
In one study, central randomisation was used and the study was
judged to have a low risk of bias for allocation concealment (Smyth
2005). Allocation concealment was not clear from the published
account in three of the studies, hence there was an unclear risk of
bias (Riethmueller 2009; Vic 1998; Whitehead 2002). Of note,
one study was a six-centre study in which three centres randomised
with three protocols and three centres randomised with two pro-
tocols (Riethmueller 2009).
Blinding
Only one study used a masked placebo and thus was judged to
have a low risk of bias (Smyth 2005). Three of the four studies
were unblinded to treatment regimen (Riethmueller 2009; Vic
1998; Whitehead 2002). Both review authors recognised that this
may have introduced bias, but decided to include the studies in
the review, whilst making this explicit.
Incomplete outcome data
We contacted the authors of the Vic study, who informed us
that no participants withdrew or were withdrawn from the study,
leading to a low risk of bias (Vic 1998). A per-protocol analysis
was performed as the primary analysis in another study as this
was an equivalence study (Smyth 2005). This is the appropriate
methodology for an equivalence study and does not increase risk of
bias. Intention-to-treat analysis was not performed in two studies
(Riethmueller 2009; Whitehead 2002). In the Riethmueller study
there is an unclear risk of bias as a per-protocol analysis was per-
formed of 30 of 38 participants (Riethmueller 2009). Likewise,
in the Whitehead study there is an unclear risk of bias as only 49
participants were studied out of the 60 who were recruited and
there is no further information on the remaining 11 participants
(Whitehead 2002).
Selective reporting
We were able to compare one study with its previously published
protocol andwe foundno evidence of selective reporting andhence
judged this study to have a low risk of bias (Smyth 2005).We were
unable to compare any protocols to final publications for any of
the other three included studies. We therefore judge there to be an
unclear risk of bias from selective reporting in these three studies
(Riethmueller 2009; Vic 1998; Whitehead 2002).
Other potential sources of bias
We were not able to identify any other potential source of bias in
the included studies.
Effects of interventions
For each outcome measure, the number of participants differed
due to incomplete data. Meta-analysis of pooled data was not
possible for the nutritional status outcome measures.
Primary outcomes
1. Lung function
a. Mean percentage change in FEV1
This result was reported in three studies with a total of 289 par-
ticipants (Smyth 2005; Vic 1998; Whitehead 2002). The mean
difference for change in FEV1 (% predicted) was 0.33 (95% confi-
dence interval (CI) -2.81 to 3.48). There was no significant differ-
ence between antibiotic regimens in the increment in FEV1 seen
with antibiotic treatment.
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b. Mean percentage change in FVC
This result was reported in two studies with a total of 70 partici-
pants (Vic 1998; Whitehead 2002). There was no significant dif-
ference between antibiotic regimens in the increment in FVC (%
predicted) seen after treatment. The mean difference for change
in FVC (% predicted) was 0.29 (95%CI -6.58 to 7.16).
c. Mean percentage change in FEF25−50%
This result was only reported in one study with 48 participants
(Whitehead 2002). Again there was no difference between regi-
mens. The mean difference for change in FEF25−50 (% predicted)
was -1.24 (95%CI -7.78 to 5.30).
Secondary outcomes
1. Nutritional status
The mean change in weight/height percentage was assessed in one
study with 22 participants (Vic 1998). The mean difference for
this outcome was -0.82 (95% CI -3.77 to 2.13), which suggests
that the mean increase in weight/height percentage was similar in
both the once-daily and thrice-daily groups.
The mean change in body mass index (BMI) was assessed in one
study with 41 participants (Whitehead 2002). The mean differ-
ence for the mean change in BMI was 0.00 (95% CI -0.42 to
0.42), this suggests that the mean increase in BMI was similar in
both the once-daily and thrice-daily groups.
2. Time to first exacerbation (requiring intravenous
antibiotics) after treatment
This was available for one study (Smyth 2005). Data for the time
to next course of intravenous antibiotics were available for 113
participants (56 on once daily, 57 on thrice daily). Median time
was 131 days (95% CI 76 to 186) for once daily and 168 days
(95% CI 34 to 302) for three-times daily treatment (P = 0·48).
3. Resistance patterns following treatment
None of the included studies reported this outcome.
4. Ototoxicity
The investigators in theRiethmueller study performed audiograms
in all patients, after treatment, and found no evidence of ototox-
icity in any patient (Riethmueller 2009). Audiograms were also
performed in the Vic study and the results were reported but did
not show any instances of ototoxicity (Vic 1998). In the White-
head study, one participant in each group was reported as expe-
riencing ototoxicity (Whitehead 2002). In the Smyth study no
participant showed deterioration in audiograms from days 1 to
14 of treatment (Smyth 2005). Two participants (one on each
regimen) reported acute dizziness and were withdrawn from the
study. In both participants, symptoms resolved without treatment.
Therefore, there was no significant difference in the relative risk of
developing ototoxicity between once and thrice-daily dosing, risk
ratio 0.56 (95% CI 0.04 to 7.96) in the four studies considered.
5. Nephrotoxicity
The measure of nephrotoxicity, which was pre-defined in the pro-
tocol, was the percentage increase in serum creatinine from base-
line. Two studies reported this outcome (Smyth 2005; Whitehead
2002). When data from the two studies were combined, there was
a non-significant trend towards a greater rise in creatinine with
once-daily treatment in adults, mean difference 3.25 (95% CI -
1.82 to 8.33). In contrast, in children, there was a significantly
smaller rise in creatinine with once-daily treatment, mean differ-
ence -8.20 (95% CI -15.32 to -1.08). Two studies measured N-
acetyl-ß-D glucosaminidase (NAG), a proximal tubular enzyme
(Smyth 2005; Riethmueller 2009). This was measured at base-
line and after 14 days of treatment in both studies. A signifi-
cantly smaller rise (less toxicity) was seen with once daily for adults
and children combined in the Smyth study (Smyth 2005). Ri-
ethmueller measured both urinary concentrations of NAG and
α-1-microglobulin (Riethmueller 2009). Both increased signifi-
cantly during treatment but there was no difference between reg-
imens. The Vic study uses creatinine clearance, lysozymuria and
microglobulinuria to assess nephrotoxicity; for microglobulinuria
there was a difference between groups on day 14 in favour of once-
daily treatment (Vic 1998).
Therefore, using the pre-defined outcome measure of percentage
change in creatinine over baseline, therewas a significant difference
in favour of once-daily treatment in children.
6. Adverse events associated with aminoglycoside infusion
None of the included studies reported this outcome.
7. Quality of life
None of the included studies reported this outcome.
D I S C U S S I O N
We set out to test the hypotheses that once-daily dosing of amino-
glycosides is as effective and nomore toxic thanmultiple-daily dos-
ing. Four studies met the inclusion criteria for this review (a total
of 320 participants contributed data). All studies used tobramycin
as the aminoglycoside of choice, dosed at either 10 mg/kg/day or
15 mg/kg/day or the dose last known to give satisfactory levels.
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In all studies, once-daily dosing was compared with thrice-daily
dosing. Whilst the three studies used the same combination of
antibiotics for all participants (Riethmueller 2009; Smyth 2005;
Vic 1998), the fourth study used different beta-lactam antibiotics
in combination with tobramycin (Whitehead 2002). Therefore,
the individual effects of different beta-lactams in this study are
unknown.
This systematic review has demonstrated no significant difference
in efficacy, measured by improvement in lung function, between
once-daily and thrice-daily dosing of tobramycin. The combined
number of participants (289) for the outcome measure of lung
function (as measured by FEV1) give sufficient statistical power to
demonstrate a true difference between regimens of 4% predicted,
if one were present.However, evidence of no greater risk of toxicity
between once-daily and thrice-daily dosing is encouraging. This
systematic review has shown that the relative risk of developing
ototoxicity between the two treatment groups was not significant.
However, the results of studies of nephrotoxicity suggested that
the rise in creatinine was significantly less in children with once-
daily treatment. In adults the effect was in favour of three-times
daily treatment, but was not significant. The magnitude of the
change in creatinine was much less than the threshold for clini-
cal renal impairment but could be clinically important, if the ef-
fect were cumulative with subsequent courses of treatment. Long-
term safety studies (which can be open label and non-randomised)
comparing the two regimens are therefore desirable. Acute renal
failure has been reported in association with aminoglycoside use
in CF and the prevalence is 100 times higher in children with CF
than in the general population (Bertenshaw 2007). The increased
risk of renal failure is associated with gentamicin use, but not with
tobramycin (Smyth 2008). Chronic exposure to aminoglycosides
has been shown to be associated with reduced creatinine clearance
(Al Aloul 2005).
When comparing once-daily and multiple-daily dosing, the ex-
pectation may be that the new treatment (once-daily dosing) is
better than the standard (thrice-daily dosing). In fact, it is more
likely that the new treatment will match the efficacy of the stan-
dard treatment but have advantages perhaps in safety, convenience
and cost. Therefore, themost useful comparison of once-daily and
multiple-daily dosing is one using the methodology for an equiv-
alence study, as suggested in a paper by Jones (Jones 1996). The
TOPIC study employed this study design (Smyth 2005).
Finally, in a chronic disorder such as CF, long-term measures of
health status are important. There was found to be no difference
in time to next exacerbation in one study (Smyth 2005). Any
differences in long-term benefits of improved lung function and
nutritional status between the two groups is unknown. Further
longitudinal studies are desirable measuring: cumulative effect on
renal function; cumulative ototoxic effect; time to the next pul-
monary exacerbation; quality of life and longitudinal changes in
the antibiotic sensitivity of P. aeruginosa.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This reviewhas demonstrated no difference in efficacy between the
two treatment regimens, although once daily appears less nephro-
toxic in children. Once-daily aminoglycoside treatment for pul-
monary exacerbations of CF may be adopted as it is more conve-
nient for people with CF. For further details of once-daily amino-
glycoside treatment the authors would like to refer readers to the
document “Antibiotic Treatment for Cystic Fibrosis” (CF Trust
2009).
Implications for research
Long-term safety studies of once-daily treatment are desirable.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Riethmueller 2009
Methods 6 centre study: 3 centres randomised with 3 protocols and 3 centres with 2 protocols.
Cross-over design.
Participants 80 participants with CF.
38 completed all 3 arms.
Interventions Once-daily dosing (10 mg/kg/day) versus thrice-daily dosing (10 mg/kg/day) of to-
bramycin.
2-week cycle.
Combination therapy with ceftazidime (200 mg/kg/day).
Outcomes Lung function: FEV1 and FVC.
Weight (kg).
Ototoxicity.
Nephrotoxicity: NAG and α-1-microglobulin.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised but no details in
paper.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No intention-to-treat analysis. 38 out of 67
completed all 3 arms of the study - data not
included on other participants
Selective reporting (reporting bias) Low risk Published protocol compared to final pa-
per.
Other bias Low risk Publication bias not identified.
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Smyth 2005
Methods 21 centres in the UK. Central randomisation, stratified by centre and adult versus pae-
diatric.
Parallel design.
Participants Per protocol analysis (n = 219).
Once daily n = 107 (63 male); age range 5.1 to 50.4 years.
Thrice daily n = 112 (68 male); age range 5.5 to 43.3 years.
Pulmonary exacerbation defined.
Interventions Once-daily dosing (10 mg/kg/day ) versus thrice-daily dosing (10 mg/kg/day) of to-
bramycin or dose last shown to give therapeutic levels.
14 days of treatment.
Combination therapy with ceftazidime.
Outcomes Lung function: FEV1 and FVC.
Weight (kg).
Ototoxicity.
Nephrotoxicity: serum creatinine & urine NAG.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation, using a computer
generated list (permuted blocks of 6), strat-
ified by centre and adult versus paediatric
Allocation concealment (selection bias) Low risk Adequate, allocation performed centrally.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo masked.
Incomplete outcome data (attrition bias)
All outcomes
Low risk A per-protocol analysis was performed as
the primary analysis as this was an equiv-
alence study. A CONSORT flow diagram
is included, giving details of participants
screened (n = 569), those enrolled (n = 244)
and those who did not complete the study
per protocol (n = 25).
Selective reporting (reporting bias) Low risk Published protocol compared to final pa-
per.
Other bias Low risk No reporting or publication bias.
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Vic 1998
Methods Randomisation table used.
Parallel design.
Participants 22 participants with diagnosis of CF.
Once daily: n = 12 (8 male); age range 5.6 - 19.3 years.
Thrice daily: n = 10 (6 male); age range 7.4 - 17.2 years.
Pulmonary exacerbation defined.
Interventions Once-daily dosing (15 mg/kg/day) versus thrice-daily dosing (15 mg/kg/day) of to-
bramycin.
14 days of treatment.
Combination therapy with ceftazidime (200 mg/kg/day).
Outcomes Lung function: FEV1 and FVC.
Weight/Height %.
Ototoxicity.
Nephrotoxicity: creatinine clearance; lysozymuria; B2-microglobulinuria; 24 hour pro-
teinuria
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation table used.
Allocation concealment (selection bias) Unclear risk No details in the published paper.
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No intention-to-treat analysis, authors
confirmed no withdrawals from the study
Selective reporting (reporting bias) Unclear risk Protocol not published in advance.
Other bias Low risk No publication bias.
Whitehead 2002
Methods Randomisation table used.
Parallel design.
Participants 60 participants with diagnosis of CF.
49 studied:
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Whitehead 2002 (Continued)
Once daily: n = 30 (16 male); age range 15 to 47 years.
Thrice daily: n = 19 (11 male); age range 16 to 32 years.
Pulmonary exacerbation defined.
Interventions Once-daily dosing (10 mg/kg/day ) versus thrice-daily dosing (10 mg/kg/day) of to-
bramycin.
12 days of treatment.
Combination therapy with beta-lactam.
Outcomes Lung function: FEV1, FVC, FEF25−75%.
Body mass index.
Ototoxicity.
Nephrotoxicity: serum creatinine.
Clinical score.
White cell count (% neutrophils).
C-reactive protein.
Participant preference.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation table used.
Allocation concealment (selection bias) Unclear risk Not described in the published paper.
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk No intention-to-treat analysis. 60 re-
cruited, 49 studied. No data given on the
remaining 11
Selective reporting (reporting bias) Unclear risk Protocol not published in advance.
Other bias Low risk No publication bias.
CF: cystic fibrosis
FEV1: forced expiratory volume at one second
FEF25−75%: forced mid-expiratory flow FVC: forced vital capacity
NAG: N-acetyl-beta-D glucosaminidase
vs: versus
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adeboyeku 2011 No once-daily arm.
Aminimanizani 2002 A pharmacokinetic paper.
Burkhardt 2006 A pharmacokinetic paper.
Hamner 2006 A pharmacokinetic paper.
Heininger 1993 Alternate allocation of treatment.
Master 2001 Trial of monotherapy versus combination therapy.
Postnikov 2007 Unclear whether randomised. Abstract only. No outcome data. No response from authors for further infor-
mation
Powell 1983 Unblinded trial with efficacy measured on a symptom score.
Winnie 1991 Comparison of tds versus qds tobramycin dosing.
Wood 1996 Comparison of bds versus tds tobramycin dosing.
bds: twice daily
qds: four times daily
tds: thrice daily
Characteristics of studies awaiting assessment [ordered by study ID]
Al Ansari 2006
Methods Cross-over RCT.
Participants Adults with CF.
Interventions Once- versus thrice-daily dosing of tobramycin for pulmonary exacerbations
Outcomes FEV1 at day 7.
Notes Authors have been approached for first-arm data.
CF: cystic fibrosis
FEV1: forced expiratory volume at one second
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RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-daily dosing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean percentage change in
FEV1
3 289 Mean Difference (IV, Fixed, 95% CI) 0.33 [-2.81, 3.48]
2 Mean percentage change in FVC 2 70 Mean Difference (IV, Fixed, 95% CI) 0.29 [-6.58, 7.16]
3 Mean change in FEF25-75 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Mean change in weight/height
%
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Mean change in body mass index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Development of ototoxicity
(after treatment)
3 266 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.04, 7.96]
7 Percentage change in creatinine
with treatment
2 245 Mean Difference (IV, Fixed, 95% CI) -0.61 [-4.74, 3.52]
7.1 Percentage change in
creatinine with treatment -
adults
2 131 Mean Difference (IV, Fixed, 95% CI) 3.25 [-1.82, 8.33]
7.2 Percentage change in
creatinine with treatment -
children
1 114 Mean Difference (IV, Fixed, 95% CI) -8.2 [-15.32, -1.08]
Analysis 1.1. Comparison 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-
daily dosing, Outcome 1 Mean percentage change in FEV1.
Review: Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
Comparison: 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-daily dosing
Outcome: 1 Mean percentage change in FEV1
Study or subgroup Once-daily Thrice-daily
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[%
pred.] N
Mean(SD)[%
pred.] IV,Fixed,95% CI IV,Fixed,95% CI
Vic 1998 12 14 (15.3) 10 14.9 (16) 5.7 % -0.90 [ -14.06, 12.26 ]
Whitehead 2002 30 10.1 (12.3) 18 9.66 (11.3) 21.2 % 0.44 [ -6.39, 7.27 ]
Smyth 2005 107 10.4 (13.8) 112 10 (14) 73.0 % 0.40 [ -3.28, 4.08 ]
Total (95% CI) 149 140 100.0 % 0.33 [ -2.81, 3.48 ]
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours thrice-daily Favours once-daily
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Analysis 1.2. Comparison 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-
daily dosing, Outcome 2 Mean percentage change in FVC.
Review: Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
Comparison: 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-daily dosing
Outcome: 2 Mean percentage change in FVC
Study or subgroup Once-daily Thrice-daily
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[%
pred.] N
Mean(SD)[%
pred.] IV,Fixed,95% CI IV,Fixed,95% CI
Vic 1998 12 10.5 (13) 10 13.8 (15) 33.6 % -3.30 [ -15.15, 8.55 ]
Whitehead 2002 30 14.3 (14.8) 18 12.2 (14.2) 66.4 % 2.10 [ -6.33, 10.53 ]
Total (95% CI) 42 28 100.0 % 0.29 [ -6.58, 7.16 ]
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours thrice-daily Favours once-daily
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Analysis 1.3. Comparison 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-
daily dosing, Outcome 3 Mean change in FEF25-75.
Review: Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
Comparison: 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-daily dosing
Outcome: 3 Mean change in FEF25−75
Study or subgroup Once-daily Thrice-daily
Mean
Difference
Mean
Difference
N
Mean(SD)[%
pred.] N
Mean(SD)[%
pred.] IV,Fixed,95% CI IV,Fixed,95% CI
Whitehead 2002 30 5.15 (12.1) 18 6.39 (10.6) -1.24 [ -7.78, 5.30 ]
-10 -5 0 5 10
Favours thrice-daily Favours once-daily
Analysis 1.4. Comparison 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-
daily dosing, Outcome 4 Mean change in weight/height %.
Review: Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
Comparison: 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-daily dosing
Outcome: 4 Mean change in weight/height %
Study or subgroup Once-daily Thrice-daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Vic 1998 12 3.14 (4.35) 10 3.96 (2.63) -0.82 [ -3.77, 2.13 ]
-4 -2 0 2 4
Favours thrice-daily Favours once-daily
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Analysis 1.5. Comparison 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-
daily dosing, Outcome 5 Mean change in body mass index.
Review: Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
Comparison: 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-daily dosing
Outcome: 5 Mean change in body mass index
Study or subgroup Once-daily Thrice-daily
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Whitehead 2002 24 0.54 (0.57) 17 0.54 (0.74) 0.0 [ -0.42, 0.42 ]
-0.5 -0.25 0 0.25 0.5
Favours thrice-daily Favours once-daily
Analysis 1.6. Comparison 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-
daily dosing, Outcome 6 Development of ototoxicity (after treatment).
Review: Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
Comparison: 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-daily dosing
Outcome: 6 Development of ototoxicity (after treatment)
Study or subgroup Once-daily Thrice-daily Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vic 1998 0/10 0/9 Not estimable
Whitehead 2002 1/18 1/10 100.0 % 0.56 [ 0.04, 7.96 ]
Smyth 2005 0/107 0/112 Not estimable
Total (95% CI) 135 131 100.0 % 0.56 [ 0.04, 7.96 ]
Total events: 1 (Once-daily), 1 (Thrice-daily)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours once-daily Favours thrice-daily
23Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-
daily dosing, Outcome 7 Percentage change in creatinine with treatment.
Review: Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
Comparison: 1 Once-daily dosing of intravenous aminoglycoside antibiotics versus multiple-daily dosing
Outcome: 7 Percentage change in creatinine with treatment
Study or subgroup Once daily Three times daily
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Percentage change in creatinine with treatment - adults
Whitehead 2002 27 5.45 (18.4) 15 0.9 (27.6) 7.0 % 4.55 [ -11.05, 20.15 ]
Smyth 2005 45 2 (12.4) 44 -1.1 (13.4) 59.3 % 3.10 [ -2.27, 8.47 ]
Subtotal (95% CI) 72 59 66.3 % 3.25 [ -1.82, 8.33 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Percentage change in creatinine with treatment - children
Smyth 2005 52 -4.5 (16.5) 62 3.7 (22.2) 33.7 % -8.20 [ -15.32, -1.08 ]
Subtotal (95% CI) 52 62 33.7 % -8.20 [ -15.32, -1.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Total (95% CI) 124 121 100.0 % -0.61 [ -4.74, 3.52 ]
Heterogeneity: Chi2 = 6.63, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 6.60, df = 1 (P = 0.01), I2 =85%
-20 -10 0 10 20
Favours once daily Favours three times
WH A T ’ S N E W
Last assessed as up-to-date: 4 February 2014.
Date Event Description
4 February 2014 New search has been performed One study by Tureen, previously listed as ’Ongoing’, has
been removed as it failed to recruit sufficient participants
and was terminated
A new search of the Cystic Fibrosis &Genetic Disorders
Group’s Cystic Fibrosis Trials Register identified no new
references which were potentially eligible for inclusion
in the review
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(Continued)
4 February 2014 New citation required but conclusions have not changed No new information has been added to this update,
hence the conclusions have remained the same
H I S T O R Y
Protocol first published: Issue 2, 2000
Review first published: Issue 4, 2000
Date Event Description
3 January 2012 New citation required but conclusions have not
changed
Additional information from the Rietmueller study
has been included, but did not change the conclusions
of the review (Riethmueller 2009).
3 January 2012 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
identified four references to three studies (Adeboyeku
2011; Al Ansari 2006; Riethmueller 2009). Two of
these were additional references (full papers) to an al-
ready included study, previously only available in ab-
stract form (Riethmueller 2009). One of the identified
references has been excluded (Adeboyeku 2011) and
the other one is currently listed as ’Awaiting classifica-
tion’ while we seek further information from the study
investigators (Al Ansari 2006).
9 September 2009 New citation required but conclusions have not
changed
This new citation has been generated as the review
teamwho worked on the updates published since Issue
3, 2007 changed from the team on previous updates.
Jayesh Bhatt is now co-author on this review
6 April 2009 New search has been performed A search of the Group’s Cystic Fibrosis Trials Regis-
ter identified three new references which were poten-
tially eligible for inclusion in the review. Two refer-
ences (Touw 2007a; Touw 2007b )were additional ref-
erences to an already included study (Smyth 2005).
One reference was excluded (Postnikov 2007).
12 November 2008 Amended Converted to new review format.
3 May 2007 Amended Kelvin Tan ceased to be actively involved with this
review as from January 2006. As of March 2007 Dr
JayeshBhatt has become an active author on this review
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(Continued)
3 May 2007 New search has been performed A search of the Group’s Cystic Fibrosis Trials Reg-
ister identified two new references (Burkhardt 2006;
Hamner 2006); these are now listed under ’Excluded
studies’.
3 May 2006 New search has been performed A new study has been included (Smyth 2005). A
further study , previously listed as “Awaiting assess-
ment”, has been added to the list of excluded studies
(Heininger 1993).
3 May 2006 New citation required and conclusions have changed Substantive amendment
27 November 2003 New search has been performed Two new references to the already includedWhitehead
2001 study have been added. Following the full pub-
lication of theWhitehead 2001 study, there have been
minor changes to data originally obtained via personal
communication
Further unpublished data from the Whitehead study
has beenmade available to the reviewers by Steve Con-
way (Leeds, UK)
27 November 2003 Amended Kelvin Tan has stepped down as lead reviewer and has
been replaced by Alan Smyth. Kelvin Tan is remaining
as a co-reviewer. Hazel Bunn has stepped down as an
active co-reviewer on this review
28 August 2001 New search has been performed The Group’s specialised register was searched in June
2001. Two studies (Master 2001; Riethmueller 2009)
were identified in the search.TheMaster study (Master
2001) was excluded as detailed in the ’Characteristics
of excluded studies’ section. The Riethmueller study
(Riethmueller 2009) was published in abstract form
only. The authors of this study kindly provided further
information, which determined that descriptive data
on efficacy would be included in the update
Two studies are still ongoing and are described in the
’Characteristics of ongoing studies’ section
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C O N T R I B U T I O N S O F A U T H O R S
Kelvin Tan prepared the protocol, selected and assessed trials and interpreted the data. He was the lead author on the review until
October 2003; from Issue 1, 2004 he was a co-author actively involved in updating the review. As from February 2006 he has ceased
to be actively involved in the review.
Hazel Evans helped to write the protocol, select and assess trials and interpret data. She also contributed to the writing of the initial
review. As of October 2003 she is no longer actively involved with the review.
Alan Smyth co-wrote the updated review and from Issue 1, 2004, is the lead author and acts as guarantor of the review.
Jayesh Bhatt joined the review as from March 2007. He has written much of the text for the updated versions of the review.
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The contact author (AS) is the principal investigator for the TOPIC study: Tobramycin Once-daily Prescribing In Cystic Fibrosis.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
None.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Aminoglycosides [∗administration & dosage]; Anti-Bacterial Agents [∗administration & dosage]; Bacterial Infections [∗drug therapy];
Cystic Fibrosis [∗complications]; Drug Administration Schedule; Drug Therapy, Combination [methods]; Injections, Intravenous;
Lung Diseases [drug therapy; microbiology]; Randomized Controlled Trials as Topic
MeSH check words
Adolescent; Adult; Child; Female; Humans; Male
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